Nicotinamide adenine dinucleotide biosynthesis promotes liver regeneration

Hepatology

Volumn 65, Issue 2, 2017, Pages 616-630

  Mukherjee, Sarmistha ^a   Chellappa, Karthikeyani ^a   Moffitt, Andrea ^a   Ndungu, Joan ^a   Dellinger, Ryan W ^b   Davis, James G ^a   Agarwal, Beamon ^a,c   Baur, Joseph A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b ChromaDex Inc   (United States)

^c DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRINKING WATER; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NICOTINAMIDE RIBOSIDE; NICOTINAMIDE; NICOTINAMIDE-BETA-RIBOSIDE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; CONTROLLED STUDY; DNA SYNTHESIS; GENE OVEREXPRESSION; HYPERGLYCEMIA; LIVER CELL; LIVER REGENERATION; MALE; MITOSIS INDEX; MOUSE; NONHUMAN; PARTIAL HEPATECTOMY; PRIORITY JOURNAL; STEATOSIS; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LIVER; LIVER RESECTION; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROCEDURES; RANDOMIZATION; SENSITIVITY AND SPECIFICITY; TRANSGENIC MOUSE;

ANIMALS; DISEASE MODELS, ANIMAL; FLUORESCENT ANTIBODY TECHNIQUE; HEPATECTOMY; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LIVER; LIVER REGENERATION; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NAD; NIACINAMIDE; RANDOM ALLOCATION; SENSITIVITY AND SPECIFICITY;

EID: 85007424227     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28912     Document Type: Article

References (46)

1. Fan ST, Lo CM, Liu CL, Yong BH, Chan JK, Ng IO. Safety of donors in live donor liver transplantation using right lobe grafts. Arch Surg 2000;135:336-340.
2. Kubota K, Makuuchi M, Kusaka K, Kobayashi T, Miki K, Hasegawa K, et al. Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology 1997;26:1176-1181.
3. Michalopoulos GK. Liver regeneration. J Cell Physiol 2007;213:286-300.
4. Ferris GM, Clark JB. Nicotinamide nucleotide synthesis in regenerating rat liver. Biochem J 1971;121:655-662.
5. Clark JB, Greenbaum AL, McLean P. The concentration and biosynthesis of nicotinamide nucleotides in the livers of rats treated with carcinogens. Biochem J 1966;98:546-556.
6. Clark JB, Pinder S. Control of the steady-state concentrations of the nicotinamide nucleotides in rat liver. Biochem J 1969;114:321-330.
7. Menyhart J, Grof J. Reinvestigation of the anaerobic glycolytic potential of the regenerating rat liver. Acta Physiol Acad Sci Hung 1972;42:129-136.
8. Frederick DW, Davis JG, Davila A Jr, Agarwal B, Michan S, Puchowicz MA, et al. Increasing NAD synthesis in muscle via nicotinamide phosphoribosyltransferase is not sufficient to promote oxidative metabolism. J Biol Chem 2015;290:1546-1558.
9. + and function in mice. Cell Metab 2015;21:706-717.
10. Mitchell C, Willenbring H. A reproducible and well-tolerated method for 2/3 partial hepatectomy in mice. Nat Protoc 2008;3:1167-1170.
11. Mitchell C, Willenbring H. Addendum: a reproducible and well-tolerated method for 2/3 partial hepatectomy in mice. Nat Protoc 2014;9.
12. Rongvaux A, Galli M, Denanglaire S, Van Gool F, Drèze PL, Szpiere C, et al. Nicotinamide phosphoribosyl transferase/pre-B cell colony-enhancing factor/visfatin is required for lymphocyte development and cellular resistance to genotoxic stress. J Immunol 2008;181:4685-4695.
13. Graeff R, Lee HC. A novel cycling assay for cellular cADP-ribose with nanomolar sensitivity. Biochem J 2002;361:379-384.
14. Borude P, Edwards G, Walesky C, Li F, Ma X, Kong B, et al. Hepatocyte-specific deletion of farnesoid X receptor delays but does not inhibit liver regeneration after partial hepatectomy in mice. Hepatology 2012;56:2344-2352.
15. Imai S, Kiess W. Therapeutic potential of SIRT1 and NAMPT-mediated NAD biosynthesis in type 2 diabetes. Front Biosci (Landmark Ed) 2009;14:2983-2995.
16. Garten A, Petzold S, Korner A, Imai S, Kiess W. Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol Metab 2009;20:130-138.
17. Garten A, Petzold S, Barnikol-Oettler A, Korner A, Thasler WE, Kratzsch J, et al. Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes. Biochem Biophys Res Commun 2010;391:376-381.
18. Soncini D, Caffa I, Zoppoli G, Cea M, Cagnetta A, Passalacqua M, et al. Nicotinamide phosphoribosyltransferase promotes epithelial-to-mesenchymal transition as a soluble factor independent of its enzymatic activity. J Biol Chem 2014;289:34189-34204.
19. Crumm S, Cofan M, Juskeviciute E, Hoek JB. Adenine nucleotide changes in the remnant liver: An early signal for regeneration after partial hepatectomy. Hepatology 2008;48:898-908.
20. Gariani K, Menzies KJ, Ryu D, Wegner CJ, Wang X, Ropelle ER, et al. Eliciting the mitochondrial unfolded protein response by nicotinamide adenine dinucleotide repletion reverses fatty liver disease in mice. Hepatology 2016; 63:1190-1204.
21. Wakil SJ, Abu-Elheiga LA. Fatty acid metabolism: target for metabolic syndrome. J Lipid Res 2009;50(Suppl.):S138-S143.
22. Burzio L, Koide SS. A functional role of polyADPR in DNA synthesis. Biochem Biophys Res Commun 1970;40:1013-1020.
23. Hoshino J, Kuhne U, Kroger H. Methylation of nicotinamide in rat liver cytosol and its correlation with hepatocellular proliferation. Biochim Biophys Acta 1982;719:518-526.
24. Shi Y, Zhang L, Jiang R, Chen W, Zheng W, Chen L, et al. Protective effects of nicotinamide against acetaminophen-induced acute liver injury. Int Immunopharmacol 2012;14:530-537.
25. Kraus D, Yang Q, Kong D, Banks AS, Zhang L, Rodgers JT, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature 2014;508:258-262.
26. Hasmann M, Schemainda I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res 2003;63:7436-7442.
27. Pauta M, Rotllan N, Fernandez-Hernando A, Langhi C, Ribera J, Lu M, et al. Akt-mediated FoxO1 inhibition is required for liver regeneration. Hepatology 2016;63:1660-1674.
28. Rudnick DA. Trimming the fat from liver regeneration. Hepatology 2005;42:1001-1003.
29. Rudnick DA, Davidson NO. Functional relationships between lipid metabolism and liver regeneration. Int J Hepatol 2012;2012:549241.
30. Tao R, Wei D, Gao H, Liu Y, DePinho RA, Dong XC. Hepatic FoxOs regulate lipid metabolism via modulation of expression of the nicotinamide phosphoribosyltransferase gene. J Biol Chem 2011;286:14681-14690.
31. + precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab 2012;15:838-847.
32. Stein TA, Burns GP, Tropp BE, Wise L. Hepatic fat accumulation during liver regeneration. J Surg Res 1985;39:338-343.
33. Garten A, Schuster S, Penke M, Gorski T, de Giorgis T, Kiess W. Physiological and pathophysiological roles of NAMPT and NAD metabolism. Nat Rev Endocrinol 2015;11:535-546.
34. Dahl TB, Holm S, Aukrust P, Halvorsen B. Visfatin/NAMPT: a multifaceted molecule with diverse roles in physiology and pathophysiology. Annu Rev Nutr 2012;32:229-243.
35. Chang BH, Li L, Paul A, Taniguchi S, Nannegari V, Heird WC, et al. Protection against fatty liver but normal adipogenesis in mice lacking adipose differentiation-related protein. Mol Cell Biol 2006;26:1063-1076.
36. Imai Y, Varela GM, Jackson MB, Graham MJ, Crooke RM, Ahima RS. Reduction of hepatosteatosis and lipid levels by an adipose differentiation-related protein antisense oligonucleotide. Gastroenterology 2007;132:1947-1954.
37. Imai Y, Boyle S, Varela GM, Caron E, Yin X, Dhir R, et al. Effects of perilipin 2 antisense oligonucleotide treatment on hepatic lipid metabolism and gene expression. Physiol Genomics 2012;44:1125-1131.
38. Najt CP, Senthivinayagam S, Aljazi MB, Fader KA, Olenic SD, Brock JR, et al. Liver-specific loss of perilipin 2 alleviates diet-induced hepatic steatosis, inflammation, and fibrosis. Am J Physiol Gastrointest Liver Physiol 2016;310:G726-G738.
39. McManaman JL, Bales ES, Orlicky DJ, Jackman M, MacLean PS, Cain S, et al. Perilipin-2-null mice are protected against diet-induced obesity, adipose inflammation, and fatty liver disease. J Lipid Res 2013;54:1346-1359.
40. Patel S, Yang W, Kozusko K, Saudek V, Savage DB. Perilipins 2 and 3 lack a carboxy-terminal domain present in perilipin 1 involved in sequestering ABHD5 and suppressing basal lipolysis. Proc Natl Acad Sci USA 2014;111:9163-9168.
41. Takahashi Y, Shinoda A, Kamada H, Shimizu M, Inoue J, Sato R. Perilipin2 plays a positive role in adipocytes during lipolysis by escaping proteasomal degradation. Sci Rep 2016;6:20975.
42. Kaushik S, Cuervo AM. Degradation of lipid droplet-associated proteins by chaperone-mediated autophagy facilitates lipolysis. Nat Cell Biol 2015;17:759-770.
43. Purushotham A, Schug TT, Xu Q, Surapureddi S, Guo X, Li X. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab 2009;9:327-338.
44. Garcia-Rodriguez JL, Barbier-Torres L, Fernandez-Alvarez S, Gutierrex-de Juan V, Monte MJ, Halilbasic E, et al. SIRT1 controls liver regeneration by regulating bile acid metabolism through farnesoid X receptor and mammalian target of rapamycin signaling. Hepatology 2014;59:1972-1983.
45. Jin J, Iakova P, Jiang Y, Medrano EE, Timchenko NA. The reduction of SIRT1 in livers of old mice leads to impaired body homeostasis and to inhibition of liver proliferation. Hepatology 2011;54:989-998.
46. Wang Y, Jiang Y, Fan X, Tan H, Zeng H, Wang Y, et al. Hepato-protective effect of resveratrol against acetaminophen-induced liver injury is associated with inhibition of CYP-mediated bioactivation and regulation of SIRT1-p53 signaling pathways. Toxicol Lett 2015;236:82-89.